Septal ablation, a valid alternative for obstructive hypertrophic cardiomyopathy

Original title: Survival of Patients ≤50 Years Alter Alcohol Septal Ablation for Hypertrofic Obstructive Cardiomyopathy. Reference: Josef Veselka, et al. Canadian Journal of Cardiology 2014,30:634-638

Treatment of symptomatic obstructive hypertrophic cardiomyopathy (HCM) is the surgical septal myomectomy nevertheless, currently arose several studies reporting a favourable evolution and comparable to surgery with septal ablation (AS). 75 patients under 50 years of age with HCM, 85 procedures were performed. The primary endpoint was all-cause mortality, and the secondary was all-cause mortality or defibrillator implant.

Average age of the population was 42 ± 7 years all symptomatic with a gradient of 73 ± 38 mmHg and the basal septum thickness of 23 ± 6 mm. Post procedure, 8% had complete AV block and 2.7% transient AV block with a need for permanent pacemaker of 6.7%. Follow-up was performed in all patients at 5.1 years showing significant improvement in functional class associated with a fall in the gradient outflow tract and decreased thickness in the basal septum.

Four patients died during follow-up (1 to 30 days by sudden death, 1 by stroke, 1 from gastrointestinal bleeding and 1 for cancer), only two were attributed to the underlying disease. Survival rates at 1, 3 and 5 years were 97%, 94%, and 94%, respectively, not being able to identify predictors of mortality in the multivariate analysis. The risk of death or need for a defibrillator was not associated with post septal ablation gradient.

Conclusion: 

This study in patients with obstructive hypertrophic cardiomyopathy (HCM) under 50 years who received septal ablation suggests a low risk of death from any cause or defibrillator implant in the long-term monitoring. 

Editorial comment 

Myomectomy remains the best strategy for those patients who are operated; however, this study showed a favourable evolution and comparable to surgery in young people; septal ablation is a less aggressive behaviour. More research is needed. 

Courtesy Dr. Carlos Fava
Interventional cardiologist
Favaloro Foundation
Argentina

Dr. Carlos Fava para SOLACI.ORG

More articles by this author

Embolization of Left Atrial Appendage Closure Devices: Predictors, Prevention, and Management Strategies

Atrial fibrillation is associated with an increased risk of stroke and, in patients with contraindications to anticoagulation, percutaneous left atrial appendage closure represents an...

Coronary revascularization before TAVI: prior PCI or conservative management?

The coexistence of coronary artery disease (CAD) in patients with severe aortic stenosis undergoing TAVI is common, with a reported prevalence ranging from 30%...

Percutaneous Mechanical Aspiration versus Surgical Treatment of Tricuspid Valve Endocarditis

Tricuspid valve infective endocarditis (TVIE) accounts for approximately 5% to 10% of all cases of infective endocarditis. Surgical treatment remains the standard therapy in...

CRT 2026 | TAVI-CLOSE Trial: Dual Suture vs Suture + Plug for Vascular Closure After Transfemoral TAVI

The transfemoral approach is the predominant strategy for transcatheter aortic valve implantation (TAVI). Although vascular complications are currently less frequent, they remain relevant determinants...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACVC 2026 | CELEBRATE Trial: Prehospital Zalunfiban Use in STEMI

Optimizing antithrombotic therapy in the prehospital phase of ST-segment elevation myocardial infarction (STEMI) remains challenging due to the delayed onset of action of P2Y12...

ACVC 2026 | BOX Substudy: Mean Arterial Pressure Targets in Cardiogenic Shock After OHCA

Hemodynamic management of cardiogenic shock following ischemic out-of-hospital cardiac arrest (OHCA-AMICS) remains an unresolved issue, particularly regarding optimal mean arterial pressure (MAP) targets and...

ACVC 2026 | FLASH Registry European Cohort: Mechanical Thrombectomy in Pulmonary Embolism

The management of intermediate-high and high-risk pulmonary embolism (PE) remains an area of therapeutic uncertainty, particularly in patients with right ventricular (RV) dysfunction, in...